Evelo Biosciences, Inc. (EVLO)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Evelo Biosciences, Inc. (EVLO) trades at $0.00 with AI Score 48/100 (Weak). Evelo Biosciences, Inc. is a clinical-stage biotechnology company focused on developing oral medicines that modulate immune cells in the small intestine to treat systemic diseases. Market cap: $9,491, Sector: Healthcare.
Last analyzed: Mar 15, 2026Evelo Biosciences, Inc. (EVLO) Healthcare & Pipeline Overview
Evelo Biosciences, Inc. pioneers oral biologics targeting the small intestine to treat systemic inflammatory diseases and cancer. With a focus on whole-microbe and non-live pharmaceutical preparations, Evelo is advancing a novel approach in immunotherapy, distinguishing itself through its oral delivery platform and pipeline of clinical-stage product candidates.
Investment Thesis
Evelo Biosciences presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's novel approach to modulating the immune system through oral biologics targeting the gut-immune axis offers a potentially disruptive alternative to injectable therapies. The successful completion of Phase 2 trials for EDP1815 in psoriasis serves as a key value driver, with further clinical development representing a significant catalyst. However, the company's reliance on early-stage clinical programs and the inherent risks associated with drug development, including regulatory hurdles and clinical trial failures, pose substantial challenges. Investors should closely monitor the progress of Evelo's clinical trials and financial runway to assess the viability of their long-term growth prospects.
Based on FMP financials and quantitative analysis
Key Highlights
- Evelo Biosciences is a clinical-stage company with no products currently approved for sale.
- Lead product candidate EDP1815 has completed Phase 2 trial for psoriasis.
- Developing EDP1867, a non-live pharmaceutical preparation, currently in Phase 1b clinical trial.
- Focus on oral medicines that act on immune cells in the small intestine with systemic effects.
- Market Cap of $0.00B reflects the early stage nature of the company and associated risks.
Competitors & Peers
Strengths
- Novel oral delivery platform.
- Targeting the gut-immune axis.
- Clinical-stage product candidates.
- Experienced management team.
Weaknesses
- Limited financial resources.
- Reliance on early-stage clinical programs.
- No approved products on the market.
- High risk of clinical trial failures.
Catalysts
- Upcoming: Phase 1b clinical trial results for EDP1867.
- Upcoming: Further clinical development of EDP1815 into additional indications.
- Ongoing: Advancement of EDP2939 through clinical trials.
- Ongoing: Progress of EDP1908 in oncology.
- Ongoing: Potential strategic partnerships and collaborations.
Risks
- Potential: Clinical trial failures.
- Potential: Regulatory hurdles.
- Potential: Competition from larger pharmaceutical companies.
- Ongoing: Limited financial resources.
- Ongoing: Reliance on early-stage clinical programs.
Growth Opportunities
- Expansion of EDP1815 into additional indications: Following the completion of Phase 2 trials for psoriasis, Evelo has the opportunity to expand the clinical development of EDP1815 into other inflammatory conditions, such as atopic dermatitis or inflammatory bowel disease. Success in these additional indications could significantly broaden the market potential for EDP1815, representing a multi-billion dollar market opportunity.
- Advancement of EDP1867 through clinical trials: EDP1867, a non-live pharmaceutical preparation, is currently in a Phase 1b clinical trial. Positive results from this trial could pave the way for further clinical development and potential commercialization. The market for therapies targeting the gut microbiome is growing, and EDP1867 could capture a significant share of this market if approved.
- Development of EDP2939 for inflammatory diseases: EDP2939, an investigational oral biologic, represents another growth opportunity for Evelo. The successful development and commercialization of EDP2939 could provide a new treatment option for patients with inflammatory diseases, addressing a significant unmet medical need.
- Progress of EDP1908 in oncology: Evelo is also developing EDP1908, a product candidate for oncology. The oncology market is a large and growing market, and successful development of EDP1908 could provide a significant revenue stream for the company. The timeline for development is uncertain, but represents a long-term growth opportunity.
- Strategic partnerships and collaborations: Evelo can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These partnerships could provide access to additional funding, expertise, and resources, enhancing Evelo's ability to bring its therapies to market.
Opportunities
- Expansion into additional indications.
- Strategic partnerships and collaborations.
- Growing market for microbiome-based therapeutics.
- Potential for breakthrough therapies.
Threats
- Competition from larger pharmaceutical companies.
- Regulatory hurdles.
- Clinical trial failures.
- Intellectual property challenges.
Competitive Advantages
- Novel oral delivery platform targeting the gut-immune axis.
- Pipeline of clinical-stage product candidates.
- Intellectual property protection for their technologies and product candidates.
- Expertise in microbiome-based therapeutics.
About EVLO
Evelo Biosciences, Inc., founded in 2014 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company dedicated to the discovery and development of a new class of medicines. These oral medicines are designed to act on immune cells located in the small intestine, triggering systemic effects to treat a range of inflammatory diseases and cancer. Evelo's approach centers on modulating the immune system through the gut-immune axis, offering a potentially more convenient and cost-effective alternative to traditional injectable biologics. The company's lead product candidate, EDP1815, is a whole-microbe formulation that has completed a Phase 2 clinical trial for the treatment of psoriasis. Evelo is also developing EDP1867, a non-live pharmaceutical preparation derived from a single strain of Veillonella parvula, currently in a Phase 1b clinical trial. Additionally, their pipeline includes EDP2939, an investigational oral biologic for inflammatory diseases, and EDP1908, a product candidate targeting oncology. Evelo's focus on oral delivery and gut-immune modulation positions them uniquely within the biotechnology landscape, aiming to provide accessible and effective therapies for patients with immune-related disorders.
What They Do
- Develop oral medicines that act on immune cells in the small intestine.
- Focus on systemic effects to treat inflammatory diseases and cancer.
- Develop whole-microbe and non-live pharmaceutical preparations.
- Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
- Target the gut-immune axis to modulate the immune system.
- Offer potentially more convenient and cost-effective alternatives to injectable biologics.
Business Model
- Develop and commercialize oral medicines targeting the gut-immune axis.
- Generate revenue through the sale of approved therapies.
- Potentially license or partner with other companies to develop and commercialize their product candidates.
- Fund research and development through venture capital and public offerings.
Industry Context
Evelo Biosciences operates within the competitive biotechnology industry, where companies are focused on developing novel therapies for various diseases. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant risks of clinical trial failures. Evelo's focus on oral biologics targeting the gut-immune axis positions it within the emerging field of microbiome-based therapeutics. The company competes with larger pharmaceutical companies and other biotechnology firms developing treatments for inflammatory diseases and cancer. The biotechnology industry is experiencing growth driven by advancements in genomics, proteomics, and personalized medicine.
Key Customers
- Patients with inflammatory diseases such as psoriasis, atopic dermatitis, and inflammatory bowel disease.
- Patients with cancer.
- Healthcare providers who prescribe Evelo's therapies.
- Pharmaceutical companies that may partner with Evelo to develop and commercialize its products.
Financials
Chart & Info
Evelo Biosciences, Inc. (EVLO) stock price: $0.00 (+0.00, +0.00%)
Latest News
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Apr 26, 2023
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Apr 25, 2023
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · May 25, 2022
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · May 24, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EVLO.
Price Targets
Wall Street price target analysis for EVLO.
MoonshotScore
What does this score mean?
The MoonshotScore rates EVLO's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
EVLO OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing securities that are not eligible for quotation on OTCQX or OTCQB. Companies in this tier may be distressed, in bankruptcy, or unwilling to provide information to the public. These securities often have limited or no financial disclosure and may be subject to significant price volatility. Investing in OTC Other securities carries substantial risk due to the lack of regulatory oversight and potential for fraud or manipulation. This tier is distinct from NYSE or NASDAQ listings, which have stringent listing requirements and ongoing compliance standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no financial disclosure.
- High price volatility.
- Potential for fraud or manipulation.
- Lack of regulatory oversight.
- Limited liquidity.
- Verify the company's legal status and registration.
- Attempt to locate and review any available financial statements.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with the company's industry and operations.
- Consult with a qualified financial advisor.
- Be extremely cautious and only invest what you can afford to lose.
- Verify the company's registration with the SEC or other regulatory agencies (if applicable).
- Check for any news articles or press releases about the company.
- Look for any independent research reports or analysis of the company.
- Assess the company's website and online presence.
- Exercise extreme caution and skepticism.
EVLO Healthcare Stock FAQ
What does Evelo Biosciences, Inc. do?
Evelo Biosciences, Inc. is a clinical-stage biotechnology company pioneering a novel approach to treating inflammatory diseases and cancer through oral medicines. These medicines are designed to act on immune cells in the small intestine, triggering systemic effects. Their lead product candidate, EDP1815, has completed a Phase 2 trial for psoriasis. Evelo's unique focus on the gut-immune axis and oral delivery aims to provide more convenient and cost-effective therapies compared to traditional injectable biologics, potentially disrupting the treatment landscape for immune-related disorders.
What do analysts say about EVLO stock?
Due to the stock data pending update, a comprehensive analyst consensus is unavailable. Generally, biotechnology companies in early clinical stages are viewed as high-risk, high-reward investments. Key valuation metrics to consider would include the potential market size for their target indications, the probability of success for their clinical trials, and the strength of their intellectual property. Investors should closely monitor clinical trial results and regulatory milestones to assess the company's growth prospects. Do not treat this as a buy or sell recommendation.
What are the main risks for EVLO?
Evelo Biosciences faces several key risks inherent to the biotechnology industry and its specific business model. Clinical trial failures represent a significant risk, as the company's product candidates are still in early stages of development. Regulatory hurdles and the need for FDA approval also pose challenges. Competition from larger pharmaceutical companies with greater resources is another factor. Additionally, Evelo's limited financial resources and reliance on early-stage clinical programs increase the company's vulnerability to setbacks and market volatility.
What are the key factors to evaluate for EVLO?
Evelo Biosciences, Inc. (EVLO) currently holds an AI score of 48/100, indicating low score. Key strength: Novel oral delivery platform.. Primary risk to monitor: Potential: Clinical trial failures.. This is not financial advice.
How frequently does EVLO data refresh on this page?
EVLO prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven EVLO's recent stock price performance?
Recent price movement in Evelo Biosciences, Inc. (EVLO) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel oral delivery platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider EVLO overvalued or undervalued right now?
Determining whether Evelo Biosciences, Inc. (EVLO) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying EVLO?
Before investing in Evelo Biosciences, Inc. (EVLO), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-15.
- Stock data pending update.
- OTC disclosure status is unknown.